Last reviewed · How we verify
incabotulinumtoxinA
IncabotulinumtoxinA is a botulinum toxin type A that blocks acetylcholine release at the neuromuscular junction, causing temporary muscle paralysis.
IncabotulinumtoxinA is a botulinum toxin type A that blocks acetylcholine release at the neuromuscular junction, causing temporary muscle paralysis. Used for Muscle spasticity associated with multiple sclerosis, Cervical dystonia, Blepharospasm.
At a glance
| Generic name | incabotulinumtoxinA |
|---|---|
| Also known as | Xeomin® |
| Sponsor | Multiple Sclerosis Center of Northeastern New York |
| Drug class | Botulinum toxin type A |
| Target | SNARE complex (synaptobrevin/VAMP) |
| Modality | Biologic |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
The drug cleaves SNARE proteins required for acetylcholine vesicle fusion and release at motor nerve terminals. This results in temporary denervation and muscle relaxation, lasting several months. It is used therapeutically to reduce muscle hyperactivity and spasticity in various neurological conditions.
Approved indications
- Muscle spasticity associated with multiple sclerosis
- Cervical dystonia
- Blepharospasm
- Hemifacial spasm
Common side effects
- Injection site pain or bruising
- Muscle weakness
- Headache
- Flu-like symptoms
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- incabotulinumtoxinA CI brief — competitive landscape report
- incabotulinumtoxinA updates RSS · CI watch RSS
- Multiple Sclerosis Center of Northeastern New York portfolio CI